Jenna Abelli

Principal, Investment

As a Principal at Anzu Partners, Jenna leads investment diligence and sourcing for the firm and provides product strategy, commercialization, and business development support to its portfolio companies. Since joining the firm in 2018, Jenna has led $30M in investments for Anzu. A trained chemical engineer, Jenna leverages technical expertise to identify opportunities in next-generation chemicals, novel materials, and life sciences. 

In 2019, she led the Series B for Sofregen, a Boston-area pioneer in soft tissue engineering born out of Tufts University. Over the last few years, her work has helped Sofregen to secure major distribution agreements and she was appointed as Sofregen’s CEO in 2023, achieving major milestones, including delivery of its first vocal restoration treatments, with results for 50+ patients published in a peer-reviewed journal. 

In 2022, Jenna led the Seed round for CytoTronics, another Boston-based company born out of Harvard University that is transforming drug discovery with its optics-free imaging platform where she serves on the Board of Directors. 

In 2023, Jenna managed the diligence process for targets for Anzu’s SPAC, leading to the recent merger with Envoy Medical, a hearing health company developing a totally implanted cochlear implant (TICI). 

Prior to Anzu Jenna was a Senior Product and Brand Manager for Cascade Maverik Lacrosse where she launched the first women’s lacrosse helmet. Earlier in her career, she managed tire line development and rubber compound development projects for Continental Tire in Germany. 

Jenna holds a B.E. in Chemical Engineering from Tufts University. She lives in New Hampshire and enjoys downhill skiing and mountain biking.